KR100528565B1 - Anti-obesity composition - Google Patents

Abstract

The present invention relates to a composition of herbal ingredients having a weight loss effect, and more particularly, to inhibit obesity due to high fat or genetic reasons, including ginseng, dermis (tangerine peel), plum extract, honey, astragalus and dietary fiber. It relates to an anti-obesity composition effective to.

Description

Anti-obesity composition

The present invention relates to a composition of herbal ingredients having a weight loss effect, and more particularly, to inhibit obesity due to high fat or genetic reasons, including ginseng, dermis (tangerine peel), plum extract, honey, astragalus and dietary fiber. It relates to an anti-obesity composition effective to.

There are many changes in eating habits due to recent economic growth and lifestyle changes. In particular, busy modern people are gaining weight and obesity due to high calorie diets such as fast food and low exercise. As a result, the incidence of various adult diseases such as arteriosclerosis, hypertension, diabetes, hemostasis, or heart disease is increasing in adults as well as children and adolescents. Recently, it has been argued that obesity should be regarded as a disease.

As the obesity population increases, the diet industry is emerging, and various approaches to diets, such as clothing, cosmetics, instruments, surgery, exercise, and the like, are being made. However, there are side effects and failure cases that occur, there is a demand for the development of supplements that can be more easily and safely implemented.

Korean Patent Registration No. 304430 relates to a food composition that is effective in preventing adult diseases such as arteriosclerosis, hyperlipidemia, liver disease, etc. containing ginseng and citrus rinds, but it has an effect of reducing blood cholesterol and triglyceride content. The effects of weight loss are hard to expect.

In addition, Korean Patent Publication No. 2001-88728 discloses an anti-obesity tea composition using herbal ingredients such as Euiin, Astragalus, Creation, Schisandra chinensis, Macmun-dong, and Seokchang-po as raw materials. However, the present invention shows that the effect is to reduce the increase rate of weight rather than weight loss effect. In addition, since only a simple weight change was measured, it was not known whether there was a significant change in body composition.

The most important thing to watch out for when losing weight is the loss of protein and water. In the change of body composition due to weight loss, it is most desirable to reduce the weight by oxidation of fat, and the decrease in protein mainly occurs only at the rapid weight change. When the body loses weight, it must maintain energy homeostasis and at the same time lose weight. Therefore, the development of a diet formulation that considers the change in body composition and energy homeostasis is required without focusing on simple weight changes only.

In order to solve the above problems, an object of the present invention is to provide a composition of natural herbal ingredients effective for weight loss.

In addition, an object of the present invention is to provide an anti-obesity composition that induces weight loss due to oxidation of fat while maintaining energy homeostasis.

The inventors have performed oral dietary diets for the compositions of the present invention to induce a significant reduction in the fat essential for body weight in genetically obese mice. These results were similar to those obtained by continuous subcutaneous injection by fusion of hormones to fat droplets [Sanchis, D, Balada, F, Grasa, MM. 1996. Oleoyl-oestrone induces the loss of body fat in rats. Int J Obesity 20, 588-594.], The result of confirming the clinical effect of the obesity inhibitory composition of the present invention. Thus, it was found to be consistent with the results obtained in lean rats showing protein storage, fat wastage, decreased food intake and progressively reduced energy expenditure. [Balada, F, Sanchis, D. and Grasa, MM. 1997. Effect of oleoyl-oestrone in liposomes on the body weight of Zucker obese rats. Int J Obesity, 21, 789-795, Sanchis, D, Balada, F. and Pico, C. 1997. Rats receiving the slimming agent oleoyl-oestrone in liposomes (Merlin-2) decrease food intake but maintain thermogenesis. Arch Physiol Biochem. 105, 663-672.].

The present invention is 20-30% by weight ginseng, 20-25% by weight dermis (tangerine peel), 17-20% by weight of plum extract, 13-15% by weight honey, 10-15% by weight based on 100% by weight of the drug and It relates to an anti-obesity composition comprising 10-15% by weight of dietary fiber. Ginseng, dermis and Astragalus use dry herbs, and the plum extract is a viscous liquid obtained by weakening the plum or juice for about 48 hours. It is widely used in folk medicine. Honey uses viscous liquid honey commercially available. Dietary fiber is a powder or granulated powder processed by indigestible dietary fiber as disclosed in the revised Food Code in 1998. It is selected from among the products that have been generalized since the 1990s and widely sold to consumers. Use

In addition, the present invention is characterized in that the anti-obesity composition is a supernatant extracted and filtered at 70-100 ° C. for 2-3 hours by adding a water of 5-10 times the weight by a conventional Chinese herbal medicine method.

The anti-obesity composition can be administered orally or parenterally during clinical administration and can be used in the form of general pharmaceutical preparations. That is, the extract of the present invention may be administered in various oral and parenteral dosage forms during actual clinical administration, and when formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, etc. that are commonly used. Is prepared using. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient such as starch, calcium carbonate, sucrose, or the like in one or more herbal extracts. (Sucrose) or lactose (Lactose), gelatin, etc. are mixed and prepared. In addition to simple excipients, lubricants such as magnesium styrate talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used. As a suppository base, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.

The present invention also relates to a dietary supplement comprising the obesity suppression composition as an active ingredient.

delete

Hereinafter, the configuration of the present invention in detail through the embodiment. However, the scope of the present invention is not limited only to the Examples.

Materials and methods

Prescription composition of the anti-obesity composition used in the embodiment is 23% by weight ginseng, 20% by weight dermis (tangerine peel), 19% by weight of plum extract, 13% by weight honey, 12% by weight Astragalus and 12% by weight dietary fiber.

Three 12-week-old female rats (350-380 g) and three male Zucker obese mice (fa / fa) (405-420 g) were used, respectively. Rats are normal under normal conditions with a total energy content (bomb calorimeter (measured with C-7000, IKA, Heitersheim, Germany) of 15.96 mJ / kg and metabolic energy of 13.73 mJ / kg (calculated as the standard component of the major components)). Breeding with pellet food. In all cases, 70.7% of the energy consists of carbohydrates, 22.2% of protein, and 7.1% of fat. Normal control females and normal male rats were sacrificed and their body weight (b.w.) was used as an indicator of body analysis.

<Example>

The control group received 0.2 ml of plain sunflower seed oil daily (one group for each gender), and the treatment group contained the obesity inhibiting composition-mixed sunflower seed oil of the present invention (one male, another female rat). Was orally dieted. The energy contained in the oral diet (0.185 g oil, 7kJ) was calculated. Treatment The dose of the composition of the present invention on experimental animals was 20 ml / kg / day, and the diet was continued for 10 days between 08.00 and 10.00 hours with the start of a light cycle each day. At the end of the experiment animals were sacrificed and blood was collected in a heparin-treated beaker to obtain plasma. Animal livers were then immediately removed, frozen in liquid nitrogen and stored at 80 ° C. The carcasses of the rats were cut, the contents of the stomach and the small intestine were weighed, and put into polyethylene bags and sterilized at 120 ° C. for 2 hours.

For blood, glucose, total cholesterol, total protein, triacylglycerol and urea content were measured with a dry-chemistry strip automated analyzer (Spotchem, Menarini, Firenze, Italy). Hydroxybutyrate (lot number 907979, Boehringer Mannheim, Mannheim, Germany) and non-esterified fatty acids (lot number 1383175, Boehringer Mannheim) were measured and free insulin and total (mainly ester) for blood samples were measured. Normalized) insulin (rat insulin kit, Amersham, Amersham, UK) was measured. Glycogen content and gross mass were measured for liver samples.

Some of the carcasses were extracted and ground, followed by water content (weight difference after 24 hours at 100 ° C), lipids [Folch, J, Lees, M, Sloane-Stanley, GH. 1957. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem. 232, 497-509.], Energy (bomb calorimeter) and nitrogen (predicted by protein using Carlo Erba NA-1500 elemental analyser in total N) [Rafecas, I, Esteve, M. and Fernandez-Lopez, JA. 1994. Whole rat protein content estimation: applicability of the Nx6. 25 Method. Br J Nutr. 72, 199-209.].

Energy intake was measured from the average amount of diet consumed per day in 2-3 rat cages. The energy increase was calculated based on the difference in energy content when the normal group, the control group, and the treatment group of the present invention were sacrificed. The 15-day average energy expenditure is measured as the difference between energy intake and energy increment, and the energy expenditure results are measured using an allometric index (ie, bw0.75) [Schmidt– Nielsen, K. Animal Physiology. Cambridge University Press. Cambridge, 1975.] method. Statistics between each group were measured by two-way anova programs and the Student's t-test (p <0.05).

Table 1 shows the change in body weight of male and female rat Zucker fa / fa induced by the oral diet of the composition at an average daily oral diet of 20 ml / kg / day dose. The results of the experiments were expressed as the average ± s.e.m. (5 different animals in each group) as a percentage of the initial body weight of each animal. ZO-F-C = female control group; ZO-F-SST = composition rat group of the present invention; ZO-M-CON = male control group; ZO-M-SST = The composition of this invention is a dietary male rat group.

% Change in weight Times (days) 0 2 4 6 8 10 ZO-F-CON 100 102.2 104.5 105.3 107.5 108.7 100 102.2 104.5 105.3 107.5 108.7 100 102.2 104.5 105.3 107.5 108.7 ZO-M-CON 100 101.5 102.4 104.8 107.5 108.1 100 101.9 103.2 105.3 109.2 109.7 100 100.5 101.4 102.6 105.7 106.2 ZO-M-SST 100 100.5 98.4 97.5 96.6 95.2 100 100.8 100.1 98.9 97.8 96.7 100 101.1 97.4 96.8 94.6 94.5 ZO-F-SST 100 97.8 97.6 95.6 94.7 89.6 100 98.5 98.4 96.3 95.2 90.7 100 96.4 96.5 94.6 92.5 87.4

In Table 1, the percentage increase in body weight was actually equivalent in male and female rats for 1% of the composition of the present invention per day, but the weight was steadily decreased in the male treated with the composition of the composition of 0.5% of the present invention per day. . On day 10, statistically significant differences were observed between the male and female rat treatment groups and their controls (p <0.05, Student's t-test).

Table 2 compares the gymnastics of female and male Zucker obese rats with oral diet of 20 ml / kg of the present invention per day compared with the control group that had only saline solution.

unit cock female p (anova) Control Invention Composition Control Invention Composition gender Invention Composition Weight gain g 36.0 ± 3.1 -16.1 ± 3 37.0 ± 4.0 -50.0 ± 3.6 0.0122 0 % 9.9 ± 0.7 -4.4 ± 1.3 8.1 ± 1.4 -13.0 ± 1.2 0.0053 0 Protein increase g 3.9 ± 1.2 0.43 ± 2.3 # 9.3 ± 4.32 -2.8 ± 2.2 # 0.7402 0.03211 % 8.5 ± 3.4 0.6 ± 4.6 # 15.1 ± 3.6 -5.3 ± 3.6 # 0.7554 0.0333 Fat increase g 6.9 ± 3.21 # -16.6 ± 3.6 20.2 ± 5.4 -16.3 ± 3.6 0.0633 0.0001 % 3.9 ± 1.6 # -10.3 ± 2.3 15.2 ± 4.6 -12.3 ± 2.5 0.0993 0.002 Increased moisture g 4.6 ± 2.4 # -16.3 ± 3.3 6.0 ± 2.2 # -34.4 ± 3.6 0.1002 0 % 3.4 ± 2.0 # -11.2 ± 2.2 3.8 ± 1.4 # -18.2 ± 2.3 0.1445 0 Total energy increase g 1110 ± 193 -221 ± 87 # 956 ± 212 -802 ± 120 0.1120 0 % 17.2 ± 2.6 -4.3 ± 1.4 # 11.6 ± 2.2 -12.1 ± 2.1 0.0400 0

* Comparison with initial figures.

No statistical difference from # 0.

Table 2 shows body composition changes in the four experimental groups of Table 1. Male rats were reduced by 4.5% of their initial body weight with 12% of females. Female rats induced about 3 times more weight loss than males, and there was no significant difference between females and males in control group. Protein changes were found in the control group but not in the treatment group. The fat reduction of the composition treatment group of the present invention was similar in both female and male rats within 10% of the initial fat storage on day 10. The total energy increase was similar in each control group, but the female treatment group decreased more than the male treatment group.

Table 3 shows the average daily dietary intake of female and male Zucker fa / fa rats in the daily saline oral diet (control) and the saline treatment group supplemented with the present composition of 20 ml / kg / day on average daily. It is shown. Each value is the average of two cages consisting of two and three rats, respectively. ZO-F-C = female control group; ZO-F-SST = the present invention composition-treated female rat group; ZO-M-C = male control group; ZO-M-SST = The composition of the present invention treated male rats. Significant differences were noted between the control diet female and male groups at day 10 (p <0.05). Both females and males were significant (p <0.05) between control and treatment groups.

Food intake (g / day) 0 (days) 2 (days) 4 (days) 6 (days) 8 (days) 10 (days) ZO-M-C 21.5 ± 2.3 24.4 ± 3.2 24.3 ± 1.6 25.0 ± 3.2 24.5 ± 1.7 24.2 ± 2.6 ZO-F-C 32.7 ± 2.1 32.5 ± 1.5 32.2 ± 2.5 31.6 ± 2.6 31.2 ± 2.7 28.2 ± 3.2 ZO-M-SST 19.6 ± 2.3 16.4 ± 0.6 13.1 ± 0.6 12.7 ± 1.5 12.0 ± 1.0 10.3 ± 0.7 ZO-F-SST 19.9 ± 2.5 19.5 ± 2.1 16.7 ± 0.9 12.4 ± 0.9 11.0 ± 1.5 6.7 ± 0.4

In Table 3, the control group of the female had a higher dietary intake than the male relative control group, but both the female and the male treated groups showed similar dietary intake. Thus, the difference between the control and treatment groups is smaller in the female group than in the male group.

Table 4 shows the energy balance compared to the control group in which only the physiological saline of Zucker female and male obese mice was mixed with 20 ml / kg of the present invention and mixed with physiological saline.

unit cock female p (anvoa) Control Invention Composition Control Invention Composition gender Invention Composition Ingestion * g / day 25.2 ± 0.5 11.2 ± 0.6 30.2 ± 0.4 1.212.2 ± 0.1003 0.0004 Energy Intake W 4.1 ± 0.1 2.2 ± 0.1 5.1 ± 0.1 2.1 ± 0.2 0.1001 0.0003 Natural increase in energy mW 1083 ± 104 192 ± 87 921 ± 233 702 ± 87 0.1100 0.000 Energy expenditure§ W 2.93 2.22 4.44 3.02 - - mW / g ^0.75 35.3 27.8 46.2 35.0 - -

* 10-day average.

Gastrointestinal diet containing 7 kJ / day from oil

## Results in Table 1.

Calculated as the difference between intake and natural incremental energy.

The overall energy balance is shown in Table 4. Treatment of the composition of the present invention reduced dietary intake by an average of 52% of the control in males but only 42% in females. The average energy consumption was reduced by 21% in males and 30% in females. The data was calibrated by the allometric factor method, and the female control group consumed 76% energy. The composition treatment of the present invention reduced energy consumption by 19% in males and 25% in females. In male rats, the naturally increased energy of the control is in the range of 37% of energy expenditure. In rats treated, the use of internal reserve energy for energy expenditure was about 8%. In female rats, the naturally increased energy of the control group was within 22% of the energy expenditure, while in treated rats the internal reserve energy use for energy expenditure was about 25%.

Table 5 shows Zucker obese rats treated with oral diet 20 ml / kg daily of plasma and hepatic energy indicators and changes in hormone levels, and control and untreated normal rats fed only saline. The result is a comparison. Data were treated with mean ± sem (5 rats in each group).

Post-hoc Duncan test: 'X' means p <0.05 significance between groups: i = intact; c = control, live = composition composition-treated group.

Table 5 shows the plasma and liver-energy indicators and levels of hormone amounts in the native mice, control and treated rats. No differences were found in the levels of aspartate-transaminase and alanine-transaminase between the groups. Obese male rats contained higher amounts of fat in the liver than female rats, but the treatment of the composition of the present invention induced constant differences. There was no particular change in liver glycogen accumulation following treatment with the composition of the present invention.

The amount of free oestrone that tends to increase due to the oral diet of the composition of the present invention was 2.3 times higher (Student's t-test) significance in female rats, but 1.2 times higher in males but not significant. Did. Total (mainly esterified) plasma ostron volume increased 1.8-fold in males and 1.9-fold in females, both in male and female. As expected, both genders resulted in a decrease in the amount of circulating glucose when treated with the composition of the present invention as compared to control and normal rats. The amount of insulin was also significantly reduced in all treated animals with the same results as in the case of glucose. This reduction has also been observed in triacylglycerols and cholesterol. There was no significant change in non-esterified fatty acids, but 3-hydroxybutyrate was decreased in control and treated rats compared to normal untreated groups.

As a result, there was a similar tendency in both male and female rats, but there was a significant difference between sexes in their responsiveness to the oral formula of the present invention. Although both males and females had similar initial weights and consumed the same amount of dietary composition of the present invention, female rats showed a more pronounced effect. In other words, dietary intake was reduced and more energy was consumed, resulting in greater weight loss. Female rats lose about twice the weight of male rats. Other strengths of the composition effects of the present invention on male and female rats did not reach metabolic indices as the effects on glucose, cholesterol, insulin and urea were similar in both sexes. However, both food intake and weight loss were higher in female rats.

Accordingly, the composition of the present invention can provide an anti-obesity composition that can effectively reduce weight through oxidation of fat while maintaining energy homeostasis.

In addition, the composition of the present invention effectively reduces weight by genetically obese or high fat diet.

Claims (3)

20-30% by weight of ginseng, 20-25% by weight of dermis (citrus peel), 17-20% by weight of plum extract, 13-15% by honey, 10-15% by weight of astragalus and 10-15% by weight of dietary fiber Obesity Inhibitory Composition. The anti-obesity composition according to claim 1, wherein the anti-obesity composition is a supernatant added with water and extracted and filtered by a conventional Chinese herbal medicine. A health supplement food comprising the obesity inhibitory composition of claim 1 or 2 as an active ingredient.